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Pseudomyxoma peritonei follows the perforation of a
mucinous appendiceal or ovarian neoplasm which leads to
intraperitoneal dissemination of mucinous implants that
range in viscosity from purely liquid to a semisolid-like
texture and that form on the peritoneal surfaces of the
abdominal wall and visceral organs.
1 Though the epithelial
cells within the mucin proliferate and result in production
of mucin, it rarely invades and hence does not metastasize
into the blood stream or lymphatics. This mucinous
material remains intra-abdominally and accumulates,
eventually causing severe abdominal distension and anor-
exia from compression of the small bowel, which are the
main causes of morbidity and mortality in untreated
patients. The intraoperative ﬁndings of extensive carcino-
matosis with mucinous implants accumulating in the pelvis
and subphrenic regions are often daunting to general sur-
geons.
2 Traditional treatments include repeated abdominal
lavage of mucin, limited debulking of tumor, and systemic
chemotherapy.
3 However, these treatments are unable to
adequately combat the reaccumulation of mucin that
characterizes the failure of these treatments.
Cytoreductive surgery and perioperative intraperitoneal
chemotherapy comprising hyperthermic intraperitoneal
chemotherapy (HIPEC) with or without postoperative
intraperitoneal chemotherapy (EPIC) has been unani-
mously regarded as the standard of care in specialized
centers.
4,5 A systematic review reporting the results of this
treatment in 10 specialized institutions of 863 patients
showed a 5-year survival ranging between 52 and 96%
from the time of cytoreductive surgery.
6 Overall survival
rates of 10 years have also been reported to be about
85%.
7,8 In our institution, our perioperative intraperitoneal
regimen comprising HIPEC and EPIC has resulted in a 5-
year survival of 75% and a median progression-free sur-
vival of 40 months.
9 Further, a subgroup of the 106
patients treated has shown that perioperative intraperito-
neal chemotherapy at the time of surgery for recurrent
disease (second operation) signiﬁcantly reduces subsequent
risk of recurrence (third operation or death from 48 to 5%)
(unpublished data). Cytoreductive surgery involves an
extensive surgical debulking through a peritonectomy
procedure and is followed by administering perioperative
intraperitoneal chemotherapy. This treatment has been
shown to reduce disease recurrence and prolong survival
compared with a policy of debulking surgery alone.
10,11
Hence emphasizing the efﬁcacious role of perioperative
intraperitoneal chemotherapy.
Perioperative intraperitoneal chemotherapy, as ﬁrst
described by Sugarbaker, comprised both intraoperative
instillation of a hyperthermic intraperitoneal chemotherapy
(HIPEC) and a postoperative instillation of normothermic
early postoperative intraperitoneal chemotherapy (EPIC).
Intraoperative instillation of chemohyperthermia has been
shown to have dual purpose to attain microscopic cytore-
duction through the heat and the cytotoxic agent. By
combiningthesetwomodalities,asynergisticeffecthasbeen
shown where the cytotoxic effect is enhanced because of the
heat.
12 EPIC is an older technique of administering intra-
peritoneal chemotherapy and is normally done during the
ﬁrst 5 postoperative days where it is intended to target any
residual microscopic tumor cells on raw peritoneal surfaces
and surgical sites before the formation of adhesions.
13
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been curtailed because of its related complications, with
the preference being to administer solely HIPEC after
surgical cytoreduction and proceeding to adjuvant systemic
treatments as required. A comparison of these two tech-
niques of administering intraperitoneal chemotherapy in a
selected cohort of 46 patients showed that EPIC was
associated with higher rates of digestive ﬁstulas (HIPEC
0% and EPIC 26%; P = .02), a poorer overall survival
(HIPEC 54% at 5 years and EPIC 28% at 5 years;
P = .22), and higher rates of intraperitoneal recurrences
(HIPEC 26% and EPIC 57%; P = .03), therefore indicat-
ing that HIPEC is better tolerated and more efﬁcient than
EPIC at targeting microscopic residual tumor cells.
14 The
relative efﬁcacy of administering HIPEC and EPIC com-
pared with HIPEC alone as part of the package of
perioperative intraperitoneal chemotherapy is unknown.
Given that the rationale of perioperative intraperitoneal
chemotherapy is to target microscopic disease, it would
seem unjustiﬁed if the contributing survival advantage of
administering EPIC after HIPEC is ignored purely for its
morbidity and the convenience of postoperative care.
We therefore propose a clinical trial to examine the rel-
ative efﬁcacy of the individual components of perioperative
intraperitoneal chemotherapy through randomizing patients
withpseudomyxomaperitoneiintoanarmthatreceivesboth
HIPEC (Mitomycin C 10–12.5 mg/m
2) and EPIC (5FU
650 mg/m
2) after surgical cytoreduction versus another arm
thatreceivesahighdoseofHIPEC(MitomycinC35 mg/m
2)
only (Fig. 1). Patients will be treated similarly on protocol
with survival analysis stratiﬁed according to disease histol-
ogy based on low-grade [diffuse peritoneal adenomuci-
nosis (DPAM) and peritoneal mucinous carcinomatosis
intermediate (PMCA-I)] and high-grade (PMCA) tumors.
15
Through this trial, the relative efﬁcacy of EPIC as part of the
perioperative intraperitoneal chemotherapy regimen or a
highdoseofHIPECalone,which waspreviouslyreportedto
be associated with signiﬁcant risk of bone marrow toxicity,
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FIG. 1 Clinical pathway for randomization of patients with pseudomyxoma peritonei
2676 T. C. Chua et al.wouldbeestablishedasevidenced-basedpractice.
16Further,
the morbidity associated with EPIC will also be elucidated
from the results of this trial. We call upon institutions
worldwide to participate in this effort to establish evidence-
based standard of care for pseudomyxoma peritonei.
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